Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. (Q52648924)
Jump to navigation
Jump to search
scientific article published on 19 March 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. |
scientific article published on 19 March 2018 |
Statements
Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo (English)
Shamir R Jacobino
Maaike Nederend
J Frederiek Reijneveld
Daan Augustijn
J H Marco Jansen
Jan Meeldijk
Karli R Reiding
C Erik Hack
1 reference
1 reference